SV Health Investors

Imbria Pharmaceuticals, founded in 2018 and headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies targeting cardiometabolic disorders. The company focuses on understanding the underlying mechanisms of these diseases, particularly energetic impairment at the cellular level, to inform its therapeutic candidates. Imbria's pipeline aims to improve the lives of patients suffering from conditions such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction by restoring or enhancing cellular energy production.

SpectraWAVE is a medical device company that develops intravascular optical imaging systems to diagnose and treat cardiovascular disease. Its technology integrates imaging and computation to help interventional cardiologists identify vulnerable plaques and guide coronary interventions, improving outcomes for patients with coronary artery disease. Headquartered in Waltham, Massachusetts, the company was founded in 2017.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, specializing in the development of bio-engineered surgical implants aimed at promoting new tissue growth and aiding in connective tissue repair. Founded in 2016, the company focuses on its innovative Bridge-Enhanced ACL Repair technology, which serves as an alternative to traditional anterior cruciate ligament (ACL) reconstruction. This technology provides surgeons with a method to restore the normal anatomy and function of the knee for patients who have experienced ACL injuries, offering a promising option for recovery and rehabilitation.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Catamaran Bio, Inc. is a biotechnology company focused on developing allogeneic CAR-NK immune cell therapies for the treatment of solid tumors and other cancers. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf CAR-NK cell therapy products. By leveraging genetic engineering, Catamaran Bio aims to address significant unmet medical needs in cancer treatment, providing transformative therapies for patients.

Amwell is a leading global telehealth platform connecting providers, insurers, patients, and innovators to deliver accessible, affordable, high-quality care. Established in 2006, Amwell offers a comprehensive platform supporting urgent to chronic care management, serving over 240 health systems, 55 health plans, and reaching over 150 million lives worldwide.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Transposon Therapeutics is a pharmaceutical company based in Westport, Connecticut. It focuses on developing therapeutics for severe and potentially fatal diseases.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

EBT Medical, Inc. is a clinical-stage company based in Boston, Massachusetts, with an additional office in Toronto, Canada. Founded in 2014, the company specializes in developing innovative, non-invasive neuromodulation therapies aimed at treating pelvic health disorders, particularly focusing on patients with overactive bladder. EBT Medical's technology is centered on the Saphenous nerve and is designed to provide discreet treatment options that enable patients to restore pelvic health function without the side effects typically associated with conventional therapies. The company emerged from scientific discoveries made at the University of Toronto and has benefited from a startup incubation program that has fostered numerous successful ventures in the past decade.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

Ribometrix is a biotechnology company that develops platform therapeutics to discover and advance small molecule drugs that target functional three-dimensional RNA structures to treat human diseases. Founded in 2014 and based in Durham, North Carolina, it focuses on leveraging RNA structure analysis and proprietary tools, along with artificial intelligence, to identify compounds that modulate RNA biology and reduce disease-associated protein production.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Ribometrix is a biotechnology company that develops platform therapeutics to discover and advance small molecule drugs that target functional three-dimensional RNA structures to treat human diseases. Founded in 2014 and based in Durham, North Carolina, it focuses on leveraging RNA structure analysis and proprietary tools, along with artificial intelligence, to identify compounds that modulate RNA biology and reduce disease-associated protein production.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

NKT Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing therapeutics based on natural killer T (NKT) cells. Established in 2008, the company focuses on creating a pipeline of first-in-class NKT-based treatments targeting a range of conditions, including sickle cell disease, autoimmune and inflammatory diseases, cancer, asthma, and dermatitis. NKT Therapeutics utilizes a unique biotechnology platform that offers humanized monoclonal antibodies to selectively deplete iNKT cells, which are implicated in organ damage in preclinical models of sickle cell disease. By leveraging its expertise in the intersection of innate and adaptive immunity, NKT Therapeutics aims to provide innovative solutions for complex health challenges.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

CardioFocus develops endoscopic ablation systems for atrial fibrillation, including the HeartLight Endoscopic Ablation System with direct visualization and energy-delivery capabilities for pulmonary vein isolation, as well as the HeartLight Excalibur Balloon and HeartLight X3 System for stable tissue contact and controlled lesion creation across varying pulmonary vein anatomies. The company integrates a balloon catheter, endoscope, deflectable sheath, and console to enable electrophysiologists to tailor ablations to patient needs. Founded in 1990 and based in Marlborough, Massachusetts, CardioFocus aims to advance treatment of cardiac arrhythmias through visualization-guided devices.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

CardioFocus develops endoscopic ablation systems for atrial fibrillation, including the HeartLight Endoscopic Ablation System with direct visualization and energy-delivery capabilities for pulmonary vein isolation, as well as the HeartLight Excalibur Balloon and HeartLight X3 System for stable tissue contact and controlled lesion creation across varying pulmonary vein anatomies. The company integrates a balloon catheter, endoscope, deflectable sheath, and console to enable electrophysiologists to tailor ablations to patient needs. Founded in 1990 and based in Marlborough, Massachusetts, CardioFocus aims to advance treatment of cardiac arrhythmias through visualization-guided devices.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

Soffio Medical, Inc. is a Boston-based company focused on developing innovative medical devices for respiratory diseases. The firm specializes in implantable technologies that aim to address chronic obstructive pulmonary disease (COPD) and similar conditions. Its devices are designed to implement an airway bypass concept, allowing for the venting of trapped air from areas distal to high-resistance airways. This approach helps reduce residual lung volume and alleviates symptoms associated with respiratory diseases, ultimately enhancing the quality of life for patients.

Deciphera Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for cancer patients. It focuses on kinase biology, leveraging its proprietary switch-control kinase inhibitor platform to create a diverse pipeline of drug candidates. Its lead product, QINLOCK®, is approved in several countries for treating fourth-line gastrointestinal stromal tumors (GIST). The company also has multiple clinical-stage and research-stage programs targeting various cancers.

Avitide, Inc. specializes in the discovery, manufacture, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, the company focuses on developing customized affinity purification products that improve the efficiency and effectiveness of bioprocessing. Avitide's technology enhances the purification of therapeutic proteins, including enzymes, antibodies, gene therapies, and vaccines, by employing rapid development of chromatography resins through chemical synthesis. This advanced platform enables clients to accelerate bioprocess development timelines, mitigate program risks, and achieve predictable commercial scalability while lowering manufacturing costs in both batch and continuous operations.

KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule protease inhibitors for diseases with unmet needs. Its primary focus is on hereditary angioedema (HAE) and diabetic macular edema (DME). The company's product portfolio includes KVD001, KVD900, and KVD824, which are in various stages of clinical trials for treating these conditions.

CardioFocus develops endoscopic ablation systems for atrial fibrillation, including the HeartLight Endoscopic Ablation System with direct visualization and energy-delivery capabilities for pulmonary vein isolation, as well as the HeartLight Excalibur Balloon and HeartLight X3 System for stable tissue contact and controlled lesion creation across varying pulmonary vein anatomies. The company integrates a balloon catheter, endoscope, deflectable sheath, and console to enable electrophysiologists to tailor ablations to patient needs. Founded in 1990 and based in Marlborough, Massachusetts, CardioFocus aims to advance treatment of cardiac arrhythmias through visualization-guided devices.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapeutics targeting chemokine receptor CXCR4. Its lead drug candidate, mavorixafor (X4P-001), is in Phase III trials for the treatment of WHIM syndrome and has shown promising results in other indications such as severe congenital neutropenia and clear cell renal cell carcinoma.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

Soffio Medical, Inc. is a Boston-based company focused on developing innovative medical devices for respiratory diseases. The firm specializes in implantable technologies that aim to address chronic obstructive pulmonary disease (COPD) and similar conditions. Its devices are designed to implement an airway bypass concept, allowing for the venting of trapped air from areas distal to high-resistance airways. This approach helps reduce residual lung volume and alleviates symptoms associated with respiratory diseases, ultimately enhancing the quality of life for patients.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Avitide, Inc. specializes in the discovery, manufacture, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, the company focuses on developing customized affinity purification products that improve the efficiency and effectiveness of bioprocessing. Avitide's technology enhances the purification of therapeutic proteins, including enzymes, antibodies, gene therapies, and vaccines, by employing rapid development of chromatography resins through chemical synthesis. This advanced platform enables clients to accelerate bioprocess development timelines, mitigate program risks, and achieve predictable commercial scalability while lowering manufacturing costs in both batch and continuous operations.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

Adimab LLC is a biotechnology company specializing in the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007 and based in Lebanon, New Hampshire, Adimab utilizes a yeast-based platform to create therapeutic antibodies, including IgG and CD3-based bispecific antibodies. The company is recognized for its ability to deliver diverse and high-quality antibody panels that adhere to stringent standards for affinity, epitope coverage, and species cross-reactivity. This capability allows Adimab to support its partners in rapidly expanding their biologics pipelines through various technology access arrangements. The company's work primarily targets the treatment of cancer, autoimmune disorders, and infectious diseases.

AlloCure, Inc. is a biotechnology company focused on developing cell therapies for kidney diseases and related conditions, including organ transplants and multi-organ injuries. Founded in 2006 and based in Burlington, Massachusetts, with additional operations in Salt Lake City, Utah, and Hamburg, Germany, AlloCure is dedicated to creating off-the-shelf biological therapies to address serious health issues affecting millions globally. The company's lead product, AC607, is a biologic therapy currently in development for acute kidney injury, with potential applications for other critical illnesses. AlloCure leverages proprietary technology utilizing processed cells derived from human bone marrow, founded by esteemed scientists Dr. Christof Westenfelder and Dr. Axel Zander, who have significant expertise in developing effective treatments for kidney diseases.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule protease inhibitors for diseases with unmet needs. Its primary focus is on hereditary angioedema (HAE) and diabetic macular edema (DME). The company's product portfolio includes KVD001, KVD900, and KVD824, which are in various stages of clinical trials for treating these conditions.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

CardioFocus develops endoscopic ablation systems for atrial fibrillation, including the HeartLight Endoscopic Ablation System with direct visualization and energy-delivery capabilities for pulmonary vein isolation, as well as the HeartLight Excalibur Balloon and HeartLight X3 System for stable tissue contact and controlled lesion creation across varying pulmonary vein anatomies. The company integrates a balloon catheter, endoscope, deflectable sheath, and console to enable electrophysiologists to tailor ablations to patient needs. Founded in 1990 and based in Marlborough, Massachusetts, CardioFocus aims to advance treatment of cardiac arrhythmias through visualization-guided devices.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for post-surgical ocular pain, inflammation, and allergic conjunctivitis, and is also being investigated for dry eye diseases. Additionally, Ocular Therapeutix is developing several other products, including OTX-TP, an intracanalicular travoprost insert for glaucoma, and OTX-TKI, an intravitreal implant for wet age-related macular degeneration, among others. The company has established a strategic collaboration with Regeneron Pharmaceuticals to leverage its hydrogel technology in combination with Regeneron's VEGF-targeting compounds for retinal diseases. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to address unmet needs in ophthalmology through its advanced therapeutic solutions.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for post-surgical ocular pain, inflammation, and allergic conjunctivitis, and is also being investigated for dry eye diseases. Additionally, Ocular Therapeutix is developing several other products, including OTX-TP, an intracanalicular travoprost insert for glaucoma, and OTX-TKI, an intravitreal implant for wet age-related macular degeneration, among others. The company has established a strategic collaboration with Regeneron Pharmaceuticals to leverage its hydrogel technology in combination with Regeneron's VEGF-targeting compounds for retinal diseases. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to address unmet needs in ophthalmology through its advanced therapeutic solutions.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

Adimab LLC is a biotechnology company specializing in the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007 and based in Lebanon, New Hampshire, Adimab utilizes a yeast-based platform to create therapeutic antibodies, including IgG and CD3-based bispecific antibodies. The company is recognized for its ability to deliver diverse and high-quality antibody panels that adhere to stringent standards for affinity, epitope coverage, and species cross-reactivity. This capability allows Adimab to support its partners in rapidly expanding their biologics pipelines through various technology access arrangements. The company's work primarily targets the treatment of cancer, autoimmune disorders, and infectious diseases.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for post-surgical ocular pain, inflammation, and allergic conjunctivitis, and is also being investigated for dry eye diseases. Additionally, Ocular Therapeutix is developing several other products, including OTX-TP, an intracanalicular travoprost insert for glaucoma, and OTX-TKI, an intravitreal implant for wet age-related macular degeneration, among others. The company has established a strategic collaboration with Regeneron Pharmaceuticals to leverage its hydrogel technology in combination with Regeneron's VEGF-targeting compounds for retinal diseases. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to address unmet needs in ophthalmology through its advanced therapeutic solutions.

NKT Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing therapeutics based on natural killer T (NKT) cells. Established in 2008, the company focuses on creating a pipeline of first-in-class NKT-based treatments targeting a range of conditions, including sickle cell disease, autoimmune and inflammatory diseases, cancer, asthma, and dermatitis. NKT Therapeutics utilizes a unique biotechnology platform that offers humanized monoclonal antibodies to selectively deplete iNKT cells, which are implicated in organ damage in preclinical models of sickle cell disease. By leveraging its expertise in the intersection of innate and adaptive immunity, NKT Therapeutics aims to provide innovative solutions for complex health challenges.

Adimab LLC is a biotechnology company specializing in the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007 and based in Lebanon, New Hampshire, Adimab utilizes a yeast-based platform to create therapeutic antibodies, including IgG and CD3-based bispecific antibodies. The company is recognized for its ability to deliver diverse and high-quality antibody panels that adhere to stringent standards for affinity, epitope coverage, and species cross-reactivity. This capability allows Adimab to support its partners in rapidly expanding their biologics pipelines through various technology access arrangements. The company's work primarily targets the treatment of cancer, autoimmune disorders, and infectious diseases.

Link Medicine is a privately held biotechnology company established in 2005 by Peter Lansbury, a prominent neuroscience researcher from Harvard University, along with Ed Rudman, a private investor diagnosed with Parkinson's disease, and entrepreneur Adam Rosenberg, who experienced the impact of neurodegenerative diseases in his family. The company focuses on advancing innovative treatments for various neurodegenerative conditions, including Alzheimer's, Parkinson's, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS). Link Medicine targets a fundamental aspect of these disorders: the accumulation of misfolded and aggregated proteins in nerve cells that can become neurotoxic. By addressing this common feature, Link Medicine aims to develop effective therapies that can alleviate the burden of these debilitating diseases.

AlloCure, Inc. is a biotechnology company focused on developing cell therapies for kidney diseases and related conditions, including organ transplants and multi-organ injuries. Founded in 2006 and based in Burlington, Massachusetts, with additional operations in Salt Lake City, Utah, and Hamburg, Germany, AlloCure is dedicated to creating off-the-shelf biological therapies to address serious health issues affecting millions globally. The company's lead product, AC607, is a biologic therapy currently in development for acute kidney injury, with potential applications for other critical illnesses. AlloCure leverages proprietary technology utilizing processed cells derived from human bone marrow, founded by esteemed scientists Dr. Christof Westenfelder and Dr. Axel Zander, who have significant expertise in developing effective treatments for kidney diseases.

Adimab LLC is a biotechnology company specializing in the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007 and based in Lebanon, New Hampshire, Adimab utilizes a yeast-based platform to create therapeutic antibodies, including IgG and CD3-based bispecific antibodies. The company is recognized for its ability to deliver diverse and high-quality antibody panels that adhere to stringent standards for affinity, epitope coverage, and species cross-reactivity. This capability allows Adimab to support its partners in rapidly expanding their biologics pipelines through various technology access arrangements. The company's work primarily targets the treatment of cancer, autoimmune disorders, and infectious diseases.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for post-surgical ocular pain, inflammation, and allergic conjunctivitis, and is also being investigated for dry eye diseases. Additionally, Ocular Therapeutix is developing several other products, including OTX-TP, an intracanalicular travoprost insert for glaucoma, and OTX-TKI, an intravitreal implant for wet age-related macular degeneration, among others. The company has established a strategic collaboration with Regeneron Pharmaceuticals to leverage its hydrogel technology in combination with Regeneron's VEGF-targeting compounds for retinal diseases. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to address unmet needs in ophthalmology through its advanced therapeutic solutions.

Adimab LLC is a biotechnology company specializing in the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007 and based in Lebanon, New Hampshire, Adimab utilizes a yeast-based platform to create therapeutic antibodies, including IgG and CD3-based bispecific antibodies. The company is recognized for its ability to deliver diverse and high-quality antibody panels that adhere to stringent standards for affinity, epitope coverage, and species cross-reactivity. This capability allows Adimab to support its partners in rapidly expanding their biologics pipelines through various technology access arrangements. The company's work primarily targets the treatment of cancer, autoimmune disorders, and infectious diseases.

Adimab LLC is a biotechnology company specializing in the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007 and based in Lebanon, New Hampshire, Adimab utilizes a yeast-based platform to create therapeutic antibodies, including IgG and CD3-based bispecific antibodies. The company is recognized for its ability to deliver diverse and high-quality antibody panels that adhere to stringent standards for affinity, epitope coverage, and species cross-reactivity. This capability allows Adimab to support its partners in rapidly expanding their biologics pipelines through various technology access arrangements. The company's work primarily targets the treatment of cancer, autoimmune disorders, and infectious diseases.

Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.

GlycoFi is a biotech company focused on developing biotherapeutics utilizing glycan optimization technology. Founded in 2000 and based in Lebanon, New Hampshire, the firm specializes in a proprietary protein manufacturing process that employs engineered yeast strains to achieve precise human glycosylation. This innovative approach enables the creation of therapeutic proteins, which are essential for drug development. GlycoFi aims to build its own pipeline of products while also collaborating with other pharmaceutical companies to enhance their drug offerings. In 2006, GlycoFi became a subsidiary of Merck & Co. Inc., further expanding its capabilities in the biotherapeutics field.

Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Founded in 2002, Alantos Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts. It specializes in the discovery and development of small molecule drugs targeting osteoarthritis, inflammation, and type II diabetes.

Insulet Corporation is a medical device company that develops, manufactures, and markets insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprises a tubeless, disposable insulin pod worn on the body for up to three days and a wireless handheld device that manages dosing, enabling automated, hands-free insulin delivery. The system is sold through independent distributors, pharmacy channels, and direct channels in the United States, Canada, Europe, and the Middle East. Insulet was founded in 2000.

Insulet Corporation is a medical device company that develops, manufactures, and markets insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprises a tubeless, disposable insulin pod worn on the body for up to three days and a wireless handheld device that manages dosing, enabling automated, hands-free insulin delivery. The system is sold through independent distributors, pharmacy channels, and direct channels in the United States, Canada, Europe, and the Middle East. Insulet was founded in 2000.

Archemix Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of therapeutic aptamers for the prevention and treatment of both chronic and acute diseases. Established in 2000, Archemix is known for its aptamer product candidates, including ARC1779, which is aimed at treating thrombotic microangiopathies and is also relevant for use in carotid endarterectomy procedures. In addition to its work in these areas, the company is developing aptamer therapeutics targeting various conditions in the fields of cardiovascular health, hematology, and oncology.

CardioFocus develops endoscopic ablation systems for atrial fibrillation, including the HeartLight Endoscopic Ablation System with direct visualization and energy-delivery capabilities for pulmonary vein isolation, as well as the HeartLight Excalibur Balloon and HeartLight X3 System for stable tissue contact and controlled lesion creation across varying pulmonary vein anatomies. The company integrates a balloon catheter, endoscope, deflectable sheath, and console to enable electrophysiologists to tailor ablations to patient needs. Founded in 1990 and based in Marlborough, Massachusetts, CardioFocus aims to advance treatment of cardiac arrhythmias through visualization-guided devices.

Phase Forward is a prominent provider of integrated data management solutions specifically designed for clinical trials and drug safety. Founded in 1997 by Paul Bleicher, M.D., Ph.D., the company aimed to transition life sciences organizations from traditional paper-based methods to innovative, Internet-enabled solutions. Its flagship product, InForm, has significantly advanced electronic data capture, transforming how clinical data is collected, analyzed, and managed. Phase Forward's technology and global services facilitate the automation and integration of the clinical development process, encompassing study initiation, FDA submission, and post-marketing studies. The company's acquisition of Lincoln Technologies enhanced its capabilities, allowing it to offer comprehensive solutions for tracking and monitoring product efficacy and safety, ultimately leading to more efficient and cost-effective trial management. Prior to its acquisition by Oracle in 2010, Phase Forward was headquartered in Waltham, Massachusetts, with additional offices in the UK, Japan, France, and Australia.

CardioFocus develops endoscopic ablation systems for atrial fibrillation, including the HeartLight Endoscopic Ablation System with direct visualization and energy-delivery capabilities for pulmonary vein isolation, as well as the HeartLight Excalibur Balloon and HeartLight X3 System for stable tissue contact and controlled lesion creation across varying pulmonary vein anatomies. The company integrates a balloon catheter, endoscope, deflectable sheath, and console to enable electrophysiologists to tailor ablations to patient needs. Founded in 1990 and based in Marlborough, Massachusetts, CardioFocus aims to advance treatment of cardiac arrhythmias through visualization-guided devices.

GelTex Pharmaceuticals develops and markets non-absorbed polymer drugs that bind and eliminate targeted substances within the gastrointestinal tract. It also develops small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators. Its focus areas include hyperphosphatemia, hypercholesterolemia, cancer, iron overload, and infectious diseases. GelTex Pharmaceutics is based in Waltham Massachusetts.